Loading organizations...
Loading organizations...
Shockwave Medical develops innovative medical devices treating calcified cardiovascular disease. Its core product, Intravascular Lithotripsy (IVL), uses a catheter system to deliver targeted ultrasonic energy, effectively fracturing arterial calcified plaque. This low-risk interventional solution improves patient outcomes by safely addressing challenging vascular calcification and enhancing procedural success.
Founded in 2009, Shockwave Medical arose from the collaborative insight of a marketer, engineer, and cardiologist. They adapted lithotripsy, a technology used for kidney stones, to safely treat calcified cardiovascular lesions. This effort transformed interventional therapy, addressing a significant unmet clinical need in vascular care.
The company's products serve physicians and patients globally with complex cardiovascular conditions. Shockwave Medical collaborates with clinical partners, ensuring innovations meet patient needs. Its vision focuses on consistently advancing the standard of care through innovative, low-risk treatment options, ultimately improving lives for underserved populations worldwide.
Shockwave Medical has raised $113.0M across 4 funding rounds.
Shockwave Medical has raised $113.0M in total across 4 funding rounds.
Shockwave Medical has raised $113.0M in total across 4 funding rounds.
Shockwave Medical's investors include Soffinova Partners.
Shockwave Medical is a medical device company that develops and commercializes Intravascular Lithotripsy (IVL) technology, using sonic pressure waves to treat calcified plaque in patients with peripheral artery disease (PAD), coronary artery disease, and heart valve conditions.[1][2][3] It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales reps and distributors, offering products like M5/M5+, S4, L6, E8 peripheral IVL catheters, C2/C2+ coronary catheters, and the Reducer for refractory angina.[1][2] The technology solves the problem of treating heavily calcified lesions that resist traditional balloon angioplasty by fracturing calcium while minimizing vessel injury and complications, with over 1 million patients treated and strong reimbursement support in coronary and peripheral IVL.[3][4][5] Now part of Johnson & Johnson MedTech since at least 2024, it demonstrates robust growth through 10 product launches since 2017, 281 global patents, and expansion into new catheters like the E8 for long, complex PAD lesions.[2][5]
Shockwave Medical emerged from Stanford Biodesign innovation, addressing the need to safely dilate heavily calcified vascular lesions in coronary and peripheral artery disease without vessel injury from high-pressure balloons.[6] Founders, including Todd Brinton (interviewed in Stanford resources), drew from early "egg-cracking" experiments proving sonic waves fracture hard calcium while sparing soft tissue, leading to the IVL platform with lithotripsy emitters on balloon catheters.[4][6] Pivotal early traction came from commercial availability in Europe and the US for peripheral artery disease, followed by coronary clearance in Europe and ongoing US IDE trials; the company has since launched 10 products since 2017, treated over 1 million IVL patients, and secured 500+ journal articles validating efficacy.[5][6] Acquired by Johnson & Johnson MedTech, it continues rapid evolution with innovations like non-balloon platforms (Javelin) and heart valve treatments.[1][2][5]
Shockwave rides the wave of rising atherosclerotic cardiovascular disease prevalence, where calcification complicates 20-30% of interventions, amid aging populations and diabetes-driven PAD growth.[1][3] Timing aligns with regulatory wins (FDA clearances like E8 in 2024) and evidence buildup (500+ publications), shifting standards from risky atherectomy/drugs to safer IVL, now treating complex cases like chronic limb-threatening ischemia (CLTI).[2][4][6] Market forces favor it: expanding PAD market, J&J integration for global distribution, and reimbursement momentum reduce barriers.[2][3][5] It influences the ecosystem by pioneering sonic tech for valves/carotids, inspiring calcium-focused medtech, and enabling better outcomes in underserved patients, with 38 R&D projects signaling broader circulatory restoration impact.[1][5]
Shockwave's J&J-backed momentum positions it for dominance in calcified cardiovascular treatments, with next steps including US Reducer approval, Javelin launches for tough lesions, and valve/carotid expansions amid 38 active R&D projects.[1][2][5] Trends like AI-guided imaging, personalized medtech, and global PAD surges will amplify IVL adoption, potentially doubling patient volumes as reimbursement solidifies.[3] Its influence evolves from niche disruptor to standard-of-care leader, making sonic waves the go-to for calcium modification—transforming underserved patients' lives as it did from Stanford labs to 1M+ treatments.[4][5][6]
Shockwave Medical has raised $113.0M across 4 funding rounds. Most recently, it raised $15.0M Series D in December 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2018 | $15.0M Series D | Soffinova Partners | |
| Nov 1, 2016 | $45.0M Series C | Soffinova Partners | |
| May 1, 2015 | $40.0M Series B | Soffinova Partners | |
| Jan 1, 2014 | $13.0M Series A | Soffinova Partners |
